EPLI for Life Sciences: When to Buy, What to Cover

EPLI sits in an unusual category. Most life sciences founders treat it as a back-burner consideration until a specific event forces attention: an employment claim, an HR-level transition, an investor diligence flag, or a headcount inflection point that triggers the conversation. The result is a program that often arrives late, gets placed reactively, and addresses the wrong exposures because the actual life sciences employment risk profile is not the generic startup employment risk profile.

This walks through when EPLI becomes a substantive coverage line for life sciences companies, the employment exposures specific to clinical staff and laboratory operations, the interaction with D&O for management-level decisions, and how investor diligence treats EPLI gaps.

When EPLI Becomes Substantive

Three triggers consistently make EPLI a real coverage decision.

Headcount inflection. The 25 to 50 employee range is where EPLI claim frequency increases meaningfully. At smaller headcounts, employment disputes happen but are typically resolved informally. As the headcount crosses into the dozens, the volume of employment decisions, the variety of employment relationships, and the operational distance between management and individual employees produce conditions where formal claims arise.

First claim or threat. A demand letter, an EEOC charge, or a state agency inquiry forces the conversation regardless of headcount. Companies that purchased EPLI before this point typically have better placement options than companies that scramble to bind coverage with an active matter on the loss runs.

Investor or acquirer diligence. Series A and later diligence routinely flags EPLI as a checklist item. Acquisition diligence treats EPLI as one of the standard coverage lines reviewed.

Specific transactional triggers. A reduction in force, a senior leadership change, a public statement or social media incident, or a high-profile termination can all surface EPLI questions independently of headcount.

For the broader stage-by-stage framing on management liability, including how EPLI typically packages with or separates from D&O at different funding stages, see D&O Insurance for Life Sciences Companies: A Stage-by-Stage Guide.

What EPLI Covers

EPLI addresses claims from current employees, former employees, and applicants, with extensions for third-party claims in some policies. The core claim categories include:

Discrimination claims. Based on protected characteristics under federal and state law: race, sex, age, disability, religion, national origin, sexual orientation, gender identity, and related categories.

Harassment claims. Sexual harassment is the most familiar category, but harassment claims based on any protected characteristic fall within EPLI.

Retaliation claims. Where an employee or former employee alleges adverse action taken in response to a protected activity (filing a complaint, requesting accommodation, whistleblower activity).

Wrongful termination. Claims that the termination violated a contract, public policy, or a protected category.

Wage and hour claims. Misclassification, overtime, off-the-clock work, meal and rest break violations. These claims have substantial statutory damages exposure under federal and state law.

Failure to accommodate. Particularly under the ADA and parallel state law, claims arising from accommodation requests that were denied or inadequately addressed.

Defamation, invasion of privacy, and related employment torts.

Third-party claims. Some policies extend to claims by non-employees (contractors, clinical site staff, customers) alleging harassment or discrimination by the insured’s personnel.

Sub-limit structure varies materially across policies. Wage and hour exposure in particular is often sub-limited inside EPLI policies, and the sub-limit adequacy is one of the more consequential structural decisions.

Life-Sciences-Specific Employment Exposure

Several employment exposure patterns are specific to or amplified within life sciences operations.

Clinical Staff

Companies employing nurses, medical assistants, clinical research coordinators, or clinicians face employment exposure that adds clinical practice scope, professional licensing, and patient interaction dimensions to standard employment claims. Disputes over scope of practice, clinical protocols, supervisory hierarchy, and professional licensure can run alongside standard employment claims.

For telehealth platforms employing clinicians, the multi-state operational footprint introduces parallel state employment regimes that affect EPLI placement structure. For the broader telehealth coverage framing, see Telehealth Platform Insurance: The Coverage Stack for Virtual Care Companies.

Sales Representatives

Medical device and diagnostic sales forces produce a recognizable cluster of employment claims. Commission disputes, territory reassignment claims, non-compete enforcement, and sales force terminations after performance plan failure are recurring categories. Sales representative wage and hour exposure is also significant, particularly around classification (exempt versus non-exempt), off-the-clock work for customer entertainment and administrative tasks, and reimbursement disputes.

Laboratory Technicians and Clinical Research Associates

Laboratory technicians, medical technologists, phlebotomists, and clinical research associates frequently work shift schedules with on-call obligations. Wage and hour exposure is elevated relative to standard office roles, with specific issues around meal and rest break compliance, on-call time compensation, travel time compensation, and overtime calculation. These exposures are particularly elevated in California and a small number of other states with strict wage and hour regimes.

Regulatory Affairs and Quality Personnel

Regulatory affairs and quality personnel often have direct access to FDA correspondence, audit findings, and compliance documentation. Retaliation claims from regulatory affairs personnel who report compliance concerns, raise audit findings, or engage in whistleblower activity can have substantial damages exposure. These claims often interact with both EPLI and D&O coverage.

International Personnel

Life sciences companies operating internationally face employment regimes that are materially different from the US framework. EU employee protections, country-specific severance frameworks, and works council requirements introduce exposures that domestic EPLI may not address. Programs need explicit attention to the international footprint.

EPLI and D&O Interaction

Employment-related management decisions sit at the intersection of EPLI and D&O. A wrongful termination claim against the company is an EPLI claim. The same termination, if it involves a board-level decision or a senior executive, may also trigger D&O.

Specific scenarios where EPLI and D&O coverage interact:

Executive terminations. Senior executive terminations frequently involve both employment claims and shareholder-level disputes. The coverage stack needs to anticipate both.

Reductions in force. Large-scale reductions can produce both individual employment claims (EPLI) and securities-related claims if the RIF was material to investor disclosure (D&O).

Compensation disputes. Equity compensation disputes can involve both employment and securities dimensions.

Whistleblower retaliation. Whistleblower claims often trigger both EPLI (employment retaliation) and D&O (regulatory action against the company or its leadership).

The structural decisions about how EPLI and D&O coordinate include the named insured structure, the priority of coverage when both policies could respond, the conduct exclusions in each policy, and the run-off considerations for departing executives.

Diligence Treatment of EPLI

Investor counsel reviews EPLI as part of the standard insurance diligence package. The mechanical checks include whether EPLI is in place, the limit adequacy relative to headcount, the wage and hour sub-limit, the named insured accuracy, and the loss run history. For the broader framing on insurance diligence, see What investors look for in a life sciences company’s insurance program during due diligence.

Specific EPLI patterns that surface as diligence flags include:

No EPLI at headcount levels where it should be in place. A clear gap.

Inadequate wage and hour sub-limit. Particularly for California operations or labor-intensive lab operations.

Recent claims activity with limited remaining limit. Loss runs reveal this.

Generic EPLI without life-sciences-specific endorsements. Policies that do not address clinical staff, sales representatives, or international employees as distinct exposures.

Misalignment between EPLI and D&O. Coverage gaps at the intersection.

Underwriting Factors

EPLI carriers writing life sciences companies evaluate several dimensions.

Headcount, headcount growth, and turnover. Rapid growth and high turnover affect underwriting.

State footprint. California, New York, Illinois, and several other states are materially harder to underwrite due to state law exposure.

HR infrastructure. Documented policies, employee handbook, training programs, complaint procedures, and dedicated HR personnel.

Claims history. Prior claims, EEOC charges, state agency complaints, and settled matters.

Employment classification practices. Independent contractor classification, exempt versus non-exempt classification, particularly for sales and technical roles.

Industry-specific exposures. Clinical staff, sales representatives, laboratory technicians, regulatory affairs personnel.

HR Documentation Carriers Expect

Specialty EPLI carriers writing life sciences companies expect specific HR documentation infrastructure to be in place. The absence of this documentation does not always disqualify the placement, but it affects terms materially.

Current employee handbook. Reviewed and updated within the last twelve months, signed acknowledgments on file, and covering the substantive employment policies (anti-harassment, anti-discrimination, complaint procedures, equal employment opportunity, accommodation, leave policies, social media policy, electronic communications policy).

Documented complaint procedure. A formal process for employees to raise concerns, with multiple reporting channels and explicit non-retaliation protection. The procedure should be documented in the handbook and operationalized.

Periodic harassment and discrimination training. Annual cadence or more frequent, with documentation of attendance and content. State-specific training requirements (California’s AB 1825 expanded requirements, New York State and City requirements, Illinois and Connecticut state-specific mandates) need to be tracked and satisfied.

Documented termination process. Pre-termination review process, manager training on documentation, and consistent application across the organization. Inconsistent or poorly documented terminations are the most common source of EPLI claims.

Classification audit. Periodic review of exempt versus non-exempt status, independent contractor classifications, and wage and hour compliance. Particularly important for sales forces and laboratory operations.

Documented offer letters and separation agreements. Templates reviewed by employment counsel, with state-specific provisions where applicable.

The presence of this infrastructure is itself underwriting evidence. Carriers reading a strong HR documentation profile underwrite more favorably than carriers reading thin or inconsistent documentation.

Common Mistakes

Buying EPLI as a checklist item rather than calibrating to actual exposure. Generic EPLI sized to headcount but not to the actual exposure profile produces gaps.

Inadequate wage and hour sub-limits. Particularly for California and other strict states, the wage and hour exposure can be the largest component of an EPLI claim.

No third-party EPLI for companies with field-based operations. Sales representatives, clinical site personnel, and third-party contractor exposure benefits from third-party coverage.

Ignoring the international footprint. US-only EPLI for companies with EU or other international employees creates a structural gap.

Letting EPLI lapse during quiet periods. Lapsed EPLI is hard to reinstate after a claim arises.

Misalignment with D&O. Coverage gaps at the EPLI-D&O intersection produce claims-handling complications.

The Placement Complexity

EPLI for life sciences companies benefits from specialty market relationships that understand the industry-specific exposures. The markets writing EPLI broadly are wide; the markets writing EPLI with attention to clinical staff, sales force exposure, and life-sciences-specific HR considerations are narrower.

The pre-binding underwriting conversation for substantive EPLI placement asks about headcount, growth trajectory, state footprint, HR infrastructure, classification practices, and prior claims. The placement is more substantive than a typical small-business EPLI bind.

A Note on Placement

MedTech Coverage works with life sciences companies on EPLI programs structured around headcount, state footprint, industry-specific exposure, and the interaction with D&O coverage. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets writing EPLI for the life sciences segment.

If an EPLI placement is being made for the first time at a headcount inflection, restructured during a Series B or growth-stage transition, or reviewed against a pending diligence process, a structured coverage review produces a working document mapped to the actual employment exposure profile.